New Insights into the Definitive Management of VTE

Understanding the Burden of VTE

Population-Based Studies: High Incidence of VTE

VTE: An Important Problem Among Hospital Patients

Percentage of Patients at Risk for VTE by Country

Percentage of At-Risk Patients Receiving Recommended

Prophylaxis

Pulmonary Embolism Carries a High Mortality Rate

Poor Clinical Outcomes After VTE Treatment

Recurrent VTE is a Common Complication

Incidence of VTE recurrence

VTE Recurrence With Continued vs Shorter VKA Treatment

Incidence of Major Bleeding With Continued vs Shorter VKA

Treatment

Post-thrombotic Syndrome

Patients With VTE are at Risk for Subsequent Development of

Venous Ulcers

Anticoagulant Control and PTS

Chronic Thromboembolic Pulmonary Hypertension

Cost Burden of VTE and Long-Term Complications

Conclusion

Anticoagulant Profiles: What You Need to Know

Currently Available Anticoagulants

Targets of “Classical” Anticoagulants: Heparin and VKAs

Warfarin -- Narrow Therapeutic Window

Challenges and Limitations of VKAs

Risks of Stroke and Mortality Associated With Suboptimal Anticoagulation in AF Patients

Anticoagulation Control and Prediction of Adverse Events in

Patients With AF

The SAMe-TT2R2 score

Targets of NOACs

Absorption and Metabolism of NOACs

NOACs in Chronic Kidney Disease

Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients

With AF

Anticoagulant Profiles: What You Need to Know

At the Crossroads: Deciding Factors for Optimizing VTE

Treatment

Conventional 2-stage Treatment of VTE

New Oral Anticoagulants

Comparisons of Designs of Phase III Acute VTE Trials

RE-COVER I and II:Efficacy and Safety Outcomes

Extended VTE Treatment With Dabigatran

EINSTEIN DVT and PE Trials:Efficacy and Safety Outcomes

EINSTEIN Extension Study

AMPLIFY

Dabigatran, Rivaroxaban, or Apixaban for VTE Treatment

What Have We Learned So Far?

AMPLIFY EXTENSION Study

What Do We Still Need to Know?

Which VTE Patients Are Candidates for New Anticoagulants?

Which VTE Patients Are Not Candidates for New

Anticoagulants?

Where is There Uncertainty for VTE Patients Using New

Anticoagulants?

Opportunities for New Oral Anticoagulants in VTE

Challenges for New Oral Anticoagulants

Conclusions

Recent Clinical Trial Data: Future Opportunities for VTE Prophylaxis and

Treatment

Introduction

Edoxaban

Background Hokusai-VTE Study

Study Outcomes

Baseline Characteristics

Severity Index Event

Efficacy Outcomes

Safety Outcomes

Pre-Specified Subgroups of Interest

Relative Efficacy Over Quartiles of Center

TTR

Relative Efficacy/Safety in 30 mg Dose Group

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)